Massive Real-World Study Finds Semaglutide Does Not Increase Diabetic Eye Disease Risk

Retrospective cohort study using 14 databases (6 administrative claims, 8 electronic health records) in the OHDSI Evidence Network. New semaglutide users for type 2 diabetes were compared to users of other GLP-1 drugs (dulaglutide, exenatide) and non-GLP-1 drugs (empagliflozin, sitagliptin, glipizide) using propensity score-adjusted Cox proportional hazards models. Network-wide estimates were generated via random-effects meta-analysis.

The SUSTAIN 6 trial flagged a potential link between semaglutide and diabetic eye complications, creating concern among clinicians and patients. This massive real-world study — covering 810,000+ patients across 14 databases — provides the most definitive evidence to date that semaglutide does not increase retinopathy risk. In fact, it may lower the risk compared to several other diabetes drugs.

This study is a landmark in resolving one of the most debated safety questions about GLP-1 drugs. By leveraging the massive OHDSI network, it provides population-level evidence that semaglutide's early clinical trial retinopathy signal does not translate into real-world harm. This should give clinicians greater confidence in prescribing semaglutide to patients with type 2 diabetes, including those at risk for eye disease.

This is a retrospective observational study, not a randomized trial, so residual confounding is possible despite propensity score adjustment. Claims and EHR data may have coding inaccuracies for eye disease diagnoses. The study period (2017–2023) may not capture very long-term effects. Patients with pre-existing severe retinopathy may have been less likely to be prescribed semaglutide, potentially biasing results.